IRIS
Narcisi, Alessandra
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 4.610
AS - Asia 3.605
SA - Sud America 1.100
EU - Europa 793
Continente sconosciuto - Info sul continente non disponibili 190
AF - Africa 116
OC - Oceania 3
AN - Antartide 1
Totale 10.418
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 4.410
SG - Singapore 2.043
BR - Brasile 864
CN - Cina 612
VN - Vietnam 548
IT - Italia 243
HK - Hong Kong 103
AR - Argentina 100
CA - Canada 97
FI - Finlandia 73
GB - Regno Unito 72
IE - Irlanda 66
IN - India 61
FR - Francia 57
DE - Germania 53
MX - Messico 53
EC - Ecuador 49
ID - Indonesia 36
RU - Federazione Russa 35
BD - Bangladesh 34
NL - Olanda 29
ZA - Sudafrica 28
NG - Nigeria 27
CO - Colombia 26
SE - Svezia 25
ES - Italia 22
PL - Polonia 22
BE - Belgio 21
UA - Ucraina 21
IQ - Iraq 20
PK - Pakistan 20
JP - Giappone 19
TR - Turchia 18
VE - Venezuela 17
MA - Marocco 14
PY - Paraguay 14
MY - Malesia 11
TN - Tunisia 11
HN - Honduras 10
CL - Cile 9
PE - Perù 9
DZ - Algeria 8
KE - Kenya 8
NP - Nepal 8
PH - Filippine 8
EG - Egitto 6
UZ - Uzbekistan 6
XK - ???statistics.table.value.countryCode.XK??? 6
AT - Austria 5
CR - Costa Rica 5
CZ - Repubblica Ceca 5
DO - Repubblica Dominicana 5
EE - Estonia 5
JM - Giamaica 5
KG - Kirghizistan 5
KZ - Kazakistan 5
LT - Lituania 5
SA - Arabia Saudita 5
TH - Thailandia 5
TT - Trinidad e Tobago 5
UY - Uruguay 5
AL - Albania 4
BO - Bolivia 4
ET - Etiopia 4
IL - Israele 4
LV - Lettonia 4
OM - Oman 4
PS - Palestinian Territory 4
AE - Emirati Arabi Uniti 3
AU - Australia 3
AZ - Azerbaigian 3
BH - Bahrain 3
CH - Svizzera 3
GE - Georgia 3
HU - Ungheria 3
KR - Corea 3
NI - Nicaragua 3
PA - Panama 3
QA - Qatar 3
RO - Romania 3
SR - Suriname 3
SV - El Salvador 3
AG - Antigua e Barbuda 2
BG - Bulgaria 2
BY - Bielorussia 2
GR - Grecia 2
GT - Guatemala 2
KW - Kuwait 2
LB - Libano 2
LY - Libia 2
MT - Malta 2
PR - Porto Rico 2
SK - Slovacchia (Repubblica Slovacca) 2
SN - Senegal 2
AO - Angola 1
AQ - Antartide 1
BA - Bosnia-Erzegovina 1
BB - Barbados 1
BN - Brunei Darussalam 1
BZ - Belize 1
Totale 10.217
Salva come PNG Salva come JPEG
Città #
Singapore 670
San Jose 502
Ashburn 422
Chandler 245
Shanghai 211
Council Bluffs 206
Dallas 200
Ho Chi Minh City 191
Beijing 180
The Dalles 167
Santa Clara 125
Los Angeles 113
New York 108
Hanoi 100
Hong Kong 100
Boardman 89
Wilmington 89
Milan 88
Helsinki 73
São Paulo 69
Dublin 66
Phoenix 46
San Mateo 45
Princeton 42
Ann Arbor 35
Brooklyn 34
Lawrence 34
Chicago 33
Buffalo 32
Haiphong 31
Benin City 27
Da Nang 26
North Bergen 26
Paris 26
Rio de Janeiro 26
Atlanta 23
Mexico City 23
Rome 22
Brussels 21
Montreal 20
Guayaquil 19
Orem 18
Warsaw 18
Belo Horizonte 17
Houston 17
London 17
Tokyo 17
Toronto 17
Hải Dương 16
Seattle 16
Amsterdam 15
Can Tho 15
Charlotte 15
Johannesburg 15
Brasília 14
Leawood 14
Boston 13
Quito 13
Assago 12
Buenos Aires 12
Chennai 12
Curitiba 12
Fairfield 12
Frankfurt am Main 12
Salvador 12
Figino 11
Philadelphia 11
Richmond 11
Ninh Bình 10
Queens 10
San Diego 10
San Francisco 10
Detroit 8
Dronten 8
Falkenstein 8
Jakarta 8
Lima 8
Miami 8
Mumbai 8
Nairobi 8
Poplar 8
Porto Alegre 8
Sorocaba 8
São Bernardo do Campo 8
Thái Bình 8
Bauru 7
Campinas 7
Caracas 7
Columbus 7
Dhaka 7
Goiânia 7
Milwaukee 7
Munich 7
Naples 7
Phủ Lý 7
Recife 7
Teresina 7
The Bronx 7
Tây Ninh 7
Uberlândia 7
Totale 5.238
Salva come PNG Salva come JPEG
Nome #
Melanoma in Adolescents and Young Adults (AYAs): An Italian Multi-Centric Retrospective Experience 213
Brodalumab: a new way to inhibit IL-17 in psoriasis 133
Chronic Hand Eczema (CHE): A Narrative Review 129
Upadacitinib improves symptoms of concomitant allergic rhinitis or allergic asthma in patients with severe atopic dermatitis: A 16-week multicentre retrospective study 126
Drug survival of IL-12/23, IL-17 and IL-23 inhibitors for moderate-to-severe plaque psoriasis: a retrospective multicenter real-world experience on 5932 treatment courses – IL PSO (Italian landscape psoriasis) 123
A fatal case of COVID-19 infection presenting with an erythema multiforme-like eruption and fever 117
Efficacy and safety of JAK inhibitors in patients aged > 60 years with moderate-to-severe atopic dermatitis: a 52-week multicenter, real-life study-IL AD (Italian Landscape Atopic Dermatitis) 109
Long-term safety and efficacy of adalimumab in psoriasis: a multicentric study focused on infections (connecting study) 105
Specific Infiltrate of Hodgkin Lymphoma at Site of Cellulitis Mimicking Secondary Cutaneous Involvement 104
A real-world economic analysis of biologic therapies for moderate-to-severe plaque psoriasis in Italy: results of the CANOVA observational longitudinal study 102
Anti-IL17 and anti-IL23 biologic drugs for scalp psoriasis: A single-center retrospective comparative study 101
Programmed cell death in the skin 100
Use of biological drugs in patients with psoriasis and psoriatic arthritis in Italy: Results from the PSONG survey 100
Apremilast for the treatment of palmo-plantar non-pustular psoriasis: A real-life single-center retrospective study 94
Complicated coronavirus disease 2019 (COVID-19) in a psoriatic patient treated with ixekizumab 93
Clinical course of COVID-19 in 41 patients with immune-mediated inflammatory diseases: Experience from humanitas center, Milan 93
Real-life Effectiveness and Safety of Risankizumab in Moderate-to-severe Plaque Psoriasis: A 40-week Multicentric Retrospective Study 92
Biologic therapies for plaque type psoriasis in patients with previous malignant cancer: long-term safety in a single- center real-life population 92
25-Hydroxyvitamin D serum levels and melanoma risk: a case-control study and evidence synthesis of clinical epidemiological studies 92
Long-term treatment with adalimumab in psoriatic arthritis: serum adalimumab concentration, immunogenicity and the link with clinical response 89
Measuring psoriatic disease in clinical practice. An expert opinion position paper 85
Effects of TNF-α inhibition on pre-clinical enthesitis: observational study on 49 psoriatic patients 85
Psychiatric comorbidity and suicidal ideation in psoriasis, melanoma and allergic disorders 83
S100A8/A9 in psoriatic plaques from patients with psoriatic arthritis 82
Reorganization of a Northern Italy dermatology department during the COVID-19 pandemic: is it temporary or the beginning of a new era in dermatology? 81
Noninvasive Assessment and Management of Folliculitis Decalvans by Trichoscopy and Reflectance Confocal Microscopy 79
A 3-Year Multicentric Study on Switching from Ustekinumab to Guselkumab in Partial Responders with Psoriasis—IL PSO (Italian Landscape Psoriasis) 78
Generalized pustular psoriasis flare in a patient affected by plaque psoriasis after BNT162b2 mRNA COVID-19 vaccine, successfully treated with risankizumab 78
A severe psoriasis flare after COVID-19 treated with risankizumab: complete skin clearance after 16 weeks 75
Anti-interleukin-17 and anti-interleukin-23 biologic drugs for genital psoriasis: a single-center retrospective comparative study 74
Potential Role of Leptin in JAK2 Inhibitor-Associated Weight Gain: A Monocentric Retrospective Study 74
Non-complicated evolution of COVID-19 infection in a patient with psoriasis and psoriatic arthritis during treatment with adalimumab 74
Long-term safety of etanercept in psoriasis: Retrospective study focused on infections 74
noveaux horizon therapeutiques pour le prurit dermatologique au delà de la dermatite atopique: role de i-modulia 74
Concomitant Pyoderma Gangrenosum-like and Amicrobial Pustulosis of the Folds: a Case Report 74
Real-Life Effectiveness and Safety of Risankizumab in 131 Patients Affected by Moderate-to-Severe Plaque Psoriasis: A 52-Week Retrospective Study 72
Diagnostic imaging: Listening in to skin disease 72
TP63 and TP73 in cancer, an unresolved "family" puzzle of complexity, redundancy and hierarchy. 72
Impact of delay in follow-up due to COVID-19 pandemic on skin cancer progression: a real-life experience from an Italian hub hospital 71
An 18-year follow-up of a case of D-penicillamine-induced Elastosis perforans serpiginosa 71
Effectiveness and safety of bimekizumab for the treatment of plaque psoriasis: a real-life multicenter study-IL PSO (Italian landscape psoriasis) 69
Palmar nodules in a young woman with ulcerative colitis and enteropathic arthritis 69
A risankizumab super responder profile identified by long-term real-life observation-IL PSO (ITALIAN LANDSCAPE PSORIASIS) 69
Real-world evidence of biologic treatments in moderate-severe psoriasis in Italy: Results of the CANOVA (EffeCtiveness of biologic treAtmeNts for plaque psOriasis in Italy: An obserVAtional longitudinal study of real-life clinical practice) study 69
Real-life effectiveness of tildrakizumab in chronic plaque psoriasis: A 52-week multicentre retrospective study-IL PSO (Italian landscape psoriasis) 68
Long-Term Effectiveness and Safety of Ixekizumab for the Treatment of Moderate-to-Severe Plaque Psoriasis: A Five-Year Multicenter Retrospective Study—IL PSO (Italian Landscape Psoriasis) 65
Suicide risk and psychiatric comorbidity in patients with psoriasis 65
Practical Use of Upadacitinib in Patients with Severe Atopic Dermatitis in a Real-World Setting: A Systematic Review 64
Brodalumab for the treatment of plaque psoriasis in a real-life setting: a 3 years multicenter retrospective study-IL PSO (Italian landscape psoriasis) 64
Efficacy and Safety of bimekizumab in elderly patients: real-world multicenter retrospective study - IL PSO (Italian Landscape Psoriasis) 63
Update on the Management of Pediatric Psoriasis: An Italian Consensus 62
Long-term effectiveness and tolerability of apremilast in patients with moderate-to-severe plaque psoriasis: A 5-year multicentre retrospective study-IL PSO (Italian landscape psoriasis) 62
Real-life Effectiveness and Safety of Guselkumab in Moderate-to-Severe Plaque Psoriasis: A 104-Week Retrospective Single-Center Study 61
Daily Patient's Relief From Pruritus and Sleep Disturbance Over One-Month Treatment with Upadacitinib in Patients with Moderate-to-Severe Atopic Dermatitis: A Multicenter Prospective Study 60
Bullous vasculitis associated with Streptococcus pyogenes sepsis 60
Anti-IL-17/23 Drugs for the Treatment of Moderate-to-Severe Hidradenitis Suppurativa in Patients With Concomitant Psoriasis: A Multicenter Retrospective Study 60
Upadacitinib 30 mg for the optimal management of moderate-to-severe atopic dermatitis: a 52-week single-center real-world study 59
What Can IBD Specialists Learn from IL-23 Trials in Dermatology? 59
Real-Life Effectiveness and Safety of Upadacitinib in Adults and Adolescents with Moderate-to-Severe Atopic Dermatitis: A Single-Center 16-Week Study 58
Pregnancy outcome of a patient treated with upadacitinib for severe atopic dermatitis 58
Urticarial rash in autoinflammatory syndromes 58
Cutaneous toxicity of CAR T-cell therapy: Case report of a bullous life-threatening reaction 57
Drug Survival of Upadacitinib and Predicting Factors of Discontinuation in Adult Patients Affected by Moderate-to-Severe Atopic Dermatitis: An Italian Multicenter Analysis 57
Biologics for the Treatment of Severe Acrodermatitis Continua of Hallopeau: Report of Two Cases Successfully Treated with Ixekizumab and Ustekinumab 57
Safety of interleukin inhibitors in patients with plaque psoriasis and history of neoplasms: a multicenter retrospective study - IL PSO (Italian landscape psoriasis) 56
Anti-IL-23 and anti-IL-17 drugs for the treatment of non-pustular palmoplantar psoriasis: a real-life retrospective study 56
Skin cancers: how to balance the risks and benefits of surgery during COVID-19 pandemic (a Northern Italy single-center experience) 56
Risk Assessment in Atopic Dermatitis: Guidance from a Multidisciplinary Expert Panel 55
Topical Pharmacological Treatment of Actinic Keratoses: Focus on Tirbanibulin 1% Ointment 55
Arrhythmias and other cardiovascular diseases in young patients (<40 years) with moderate/severe atopic dermatitis: A multicentric study in northern Italy 55
Fingertip dermatitis: a spy for psoriasis 55
An unusual case of annular bollous eruption of the inguinal folds 54
Gender Influence on Bimekizumab Response in Patients with Psoriasis: Results of a Real-World Multicenter Retrospective Study-IL PSO (Italian Landscape PSOriasis) 54
A Multidisciplinary Approach Is Beneficial in Atopic Dermatitis 54
Effectiveness of risankizumab in plaque psoriasis with involvement of difficult-to-treat areas: a real-world experience from two referral centers 54
Apremilast for the treatment of pustular psoriasis induced by neoadjuvant ifosfamide + etoposide chemotherapy for Ewing Sarcoma: a case report 54
Disseminated Superficial Porokeratosis with Dermal Amyloid Deposits 53
Safety of anti-IL-23 drugs in patients with moderate-to-severe plaque psoriasis and previous tuberculosis infection: a monocentric retrospective study 53
Real-life effectiveness and safety of guselkumab in patients with psoriasis who have an inadequate response to ustekinumab: A 104-week multicenter retrospective study – IL PSO (ITALIAN LANDSCAPE PSORIASIS) 53
A case of cutaneous large B-cell lymphoma of the legs appearing as chronic venous ulceration 53
A case of lichen amyloidosus treated with acitretin 53
An updated safety review of Hidradenitis Suppurativa treatment options 52
Intra-Class Switch Among IL-23 Inhibitors for Plaque Psoriasis: Is It Worth It? 52
Risankizumab for the treatment of genital psoriasis: A 1-year, real-world experience 51
Intra-class switch among interleukin-17 inhibitors for the treatment of plaque psoriasis: a single-center experience 51
Effectiveness of ixekizumab for the treatment of moderate‐to‐severe plaque psoriasis with involvement of difficult‐to‐treat areas: A 52‐week multicenter retrospective study 51
A Case of Ketron-Goodman Disease 51
Real-World Effectiveness and Safety of Upadacitinib and Abrocitinib in Moderate-to-Severe Atopic Dermatitis: A 52-Week Retrospective Study 50
Allergy to nickel: first results on patients administered with an oral hyposensitization therapy 50
Cutaneous hypersensitivity to gluten 50
Bimekizumab for the Treatment of Plaque Psoriasis With Involvement of Genitalia: A 16-Week Multicenter Real-World Experience—IL PSO (Italian Landscape Psoriasis) 50
Optimizing Tildrakizumab Dosing in Psoriasis: A 52-Week Multicenter Retrospective Study Comparing 100 mg and 200 mg-IL PSO (Italian Landscape Psoriasis) 50
A case of periocular contact dermatitis caused by cypress allergy 49
Successful use of tralokinumab for the treatment of atopic dermatitis on the genitals 49
Effectiveness and safety of upadacitinib for moderate‐to‐severe atopic dermatitis in a real‐world setting: A 52‐week retrospective study 49
Autoreactivity to self-antigens LL37 and ADAMTSL5 influences the clinical response to risankizumab in psoriatic patients 49
Atypical facial pustular folliculitis by Klebsiella pneumoniae: a case report 49
Secukinumab in Patients with Psoriasis and a Personal History of Malignancy: A Multicenter Real-Life Observational Study 48
Safety of Biologic Therapies in Patients with Moderate-to-Severe Plaque Psoriasis and Concomitant Viral Hepatitis: A Monocentric Retrospective Study 48
Management of Patients Affected by Moderate-to-Severe Atopic Dermatitis with JAK Inhibitors in Real-World Clinical Practice: An Italian Delphi Consensus 47
Totale 7.097
Salva come PNG Salva come JPEG
Categoria #
all - tutte 53.978
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 53.978
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/2022147 0 0 0 31 1 0 9 21 13 17 46 9
2022/2023609 82 48 46 87 59 45 1 48 99 47 41 6
2023/2024623 25 49 126 27 15 60 60 66 16 20 64 95
2024/20251.333 15 22 19 18 8 111 94 68 170 242 215 351
2025/20265.532 689 407 537 854 297 228 1.079 319 305 301 214 302
2026/20272.009 470 380 892 267 0 0 0 0 0 0 0 0
Totale 10.418